Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to understand how well a booster dose of the MVA-BN vaccine works over a long period of time in protecting against monkeypox. The researchers want to see if giving an extra dose of this vaccine can help maintain strong immunity in people who have already received two doses.

To join the study, participants need to be men over 18 years old who have already had two doses of the MVA-BN vaccine and are eligible for a booster shot, following specific health guidelines. They should also be planning to start or continue HIV prevention treatment and have social security coverage. The trial is not yet recruiting participants, but once it starts, those who qualify can expect to receive the booster dose and help researchers learn more about the vaccine's effectiveness. This study is important for improving our understanding of how to keep people safe from monkeypox.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men aged over 18 years
• • Have received two doses of MVA-BN vaccine as an initial schedule
• • Eligible for a booster dose of MVA-BN (according to the HAS recommendation)
• • Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment
• • Covered by social security (excluding AME)
• Exclusion Criteria:
• • History of mpox (virologically confirmed)
• • Be under guardianship or curatorship
• • Be subject to a judicial protection measure
• • Have a contraindication to vaccination against mpox